Open company graph database — free web & API
Login

MicroPort Orthopedics Inc.

マイクロポート整形外科株式会社Alias
Ticker
—
Listed market
—
Country
China
Employees (non-consolidated)
—
Related companies
1
§01

Basic information

BASIC
Head office
Zhangjiang Science City, Shanghai, China
Chief executive
Employees (non-consolidated)
Employees (consolidated)
Start date
1998-05-15
End date
§02

Websites

1 DOMAINS
§03

Business

11
Robotic surgical systems for orthopedicsClinical education and training servicesCustomer support and clinical assistanceinterventional treatment of coronary artery-related diseasescoronary stent systemsballoon cathetersOCT imaging cathetersresearch and developmentproductionmarketingservices
§04

Related companies

1 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
MicroPort Scientific Corporation
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

105 EVENTS

MicroPort® was founded in 1998 in a small office in ZJ Hi-Tech Park in Shanghai, by a group of dedicated individuals who shared the belief that advancements in medical technology could transform patients’ lives.Sources

Founded on May 15, 1998 at an incubation center in Zhangjiang Hi-Tech Park, Shanghai.Sources

PTCA balloon dilatation catheter received SFDA approval, very first sale made.Sources

Mustang™ bare metal stent received SFDA approval.Sources

Received major funding from National Development and Reform Commission.Sources

Officially entered Japan market with PTCA Balloon dilatation catheters.Sources

Firebird™ drug eluting stent system received SFDA approval.Sources

Mustang™ coronary stent system received CE mark.Sources

Aegis Bifurcated Stent-Graft System was named National key new product.Sources

Annual sales exceeded 100 million RMB.Sources

Hercule® Thoracic Stent-Graft System received SFDA approval.Sources

Coronary drug eluting stent implants reached over 100,000 units.Sources

Firebird™ coronary drug eluting stent system won State Science and Technology Advancement Award.Sources

Shanghai MicroPort Lifesciences Co., Ltd. was established, officially entered diabetes business; diversified business strategy implemented.Sources

Began experimental implementation of "Vertical Integration & Horizontal Connection" management model.Sources

Firebird2™ coronary drug-eluting stent system received registration approval from SFDA.Sources

Shanghai MicroPort Orthopedics Co., Ltd. was established.Sources

MicroPort Scientific Corporation listed on Hong Kong Stock Exchange (00853.HK).Sources

Annual sales exceeded 100 million USD.Sources

Shanghai MicroPort EP MedTech Co., Ltd. was established.Sources

MicroPort Medical (Jiaxing) Co., Ltd. was established.Sources

Undertook national R&D projects accumulating to more than 100 million RMB.Sources

Shanghai MicroPort Orthopedics Co., Ltd. acquired Suzhou Best Co., Ltd.Sources

Initiated “10+5” Operating Model.Sources

Shanghai MicroPort® NeuroTech Co., Ltd., Shanghai MicroPort Endovascular MedTech Co., Ltd. and MicroPort Surgical (Shanghai) Co., Ltd. were established.Sources

Acquired D-Pulse Medical (Beijing) Co., Ltd. and Dongguan Kewei Medical Instrument Co., Ltd.Sources

MicroPort® Orthopedics Global Headquarter was established in Arlington, TX, USA.Sources

Globalization Strategy Implemented.Sources

Firehawk® rapamycin target eluting coronary stent system received CFDA approval.Sources

WILLIS® clinical application project won State Science and Technology Advancement Award.Sources

Signed joint venture agreement with Sorin Group for China's cardiac rhythm management business.Sources

Acquired drug eluting stent related assets and intellectual properties from Cordis.Sources

Moved into new headquarter on at 1601 Zhangdong Rd, Zhangjiang Hi-tech Park.Sources

Annual sales exceeded 2 billion RMB.Sources

MicroPort® Innovation Platform won State Science and Technology Advancement Award.Sources

Firehawk® Rapamycin Target Eluting Coronary Stent received CE mark.Sources

EVOLUTION® medial-pivot knee system received CFDA approval.Sources

MicroPort Sorin CRM (Shanghai) Co., Ltd. launched China's first domestic pacemaker production line.Sources

MicroPort Suzhou OrthoRecon Co., Ltd. and MicroPort Suzhou Orthopedic Instruments Co., Ltd. were established in Suzhou Industrial Zone.Sources

MicroPort Surgical Robotics Co., Ltd. and MicroPort Online Co., Ltd. were established.Sources

Founded in 2015, MicroPortSources

New Technology and Clinical Application of Minimally Invasive Cardiac Surgery project won the State Science and Technology Advancement Award.Sources

Proposed to acquire the cardiac rhythm management business of LivaNova for $190 million in cash.Sources

AAA/TAA stent graft series product critical technical development and large-scale industrialization won State Science and Technology Award.Sources

Rega® Family Implantable Pacemakers and Firefighter™ PTCA Balloon Catheters received CFDA approval.Sources

The data of Firehawk® TARGET AC clinical trial showed the 3-month stent strut cover rate was of 99.9%, 5-year follow-up data of TARGET I RCT showed stent thrombus rate was 0.Sources

Medial-Pivot Knee arthroplasty system demonstrated high survivorship (98.8%) and patient satisfaction (95%) in a 17-year follow-up study.Sources

Firesorb® pivotal study FUTURE II trial completed first enrollment.Sources

MicroPort® CardioFlow brought in strategic investors.Sources

MicroPort® EP quoted on NEEQ.Sources

MicroPort Urocare Co., Ltd. established, marking the company's official entry in urology and gynecology sectors.Sources

MicroPort® Jiaxing park established.Sources

Acquired Brazil distributors to implement localized management on the Brazil market.Sources

Firehawk® clinical data from the Target AC European clinical trial has been accepted for publication in the prestigious medical journal The Lancet.Sources

Tubridge® Vascular Reconstruction Device was launched.Sources

Firehawk® and Firebird2® gained regulatory approval in Taiwan.Sources

First implantation of Rega® Family Implantable Pacemakers.Sources

Global aggregated implantations of coronary artery stent system, artificial joint implants and pacemakers reached 4.5 million, 1.1 million and 1 million respectively.Sources

MicroPort® CRM global headquarter was established in Clamart, France.Sources

MicroPort Orthopedics (Suzhou) Co., Ltd. was established.Sources

Every 12 seconds, a MicroPort® product was used across the world.Sources

SoSuperior™ Medial Stability Total Knee Replacement System and Aspiration™ Medial Pivot Total Knee Replacement System gained approval in China.Sources

MicroPort® Obtained CE Mark for Firehawk Liberty™, a New Generation Rapamycin Target Eluting Coronary Stent System.Sources

The 24 months results of the Firehawk® TARGET AC trial were announced in EuroPCR 2019, and would be published in the Journal of the American College of Cardiology (JACC).Sources

Every 6 seconds, a MicroPort® product was used across the world.Sources

The MicroPort Group and its associated companies introduced external financing of over US$1 billion accumulatively and widely recognized by the capital market.Sources

MicroPort® CardioFlow Medtech was listed on the Main Board of the Hong Kong Stock ExchangeSources

MicroPort® MedBot® was listed on the Main Board of the Hong Kong Stock ExchangeSources

MicroPort® CRM introduced the Alizea™ and Borea™ pacemakers equipped with Bluetooth technology and the SmartView Connect™ home monitor in Europe.Sources

MicroPort® CRM Navigo™ left ventricular pacing leads received CE mark approval in EuropeSources

MicroPort NeuroTech™ U-track Intracranial Support Catheter System became commercially available in the marketSources

EverPace Disposable Cardiac Mapping Leads became commercially available in the marketSources

Firefighter™ and Foxtrot® Pro PTCA Balloon Dilatation Catheter approved for marketing in Pakistan and Bosnia and HerzegovinaSources

HorizonMedical™ Daylily® Embryo Transfer Catheter approved for marketing in ThailandSources

Four products including Firehawk® Stent and Firefighter™ PTCA Balloon Dilatation Catheter received registration and marketing approval in Saudi ArabiaSources

Firefighter™ NC received registration approval in Taiwan.Sources

MicroPort NeuroTech was listed on the Main Board of the Hong Kong Stock ExchangeSources

MicroPort MedBot Skywalker™ Orthopedic Surgical Robot received NMPA approval in China, FDA 510(k) approval in the US and CE mark approval in EuropeSources

MicroPort NeuroTech Diveer® Intracranial Balloon Catheter, Neurohawk® Stent Thrombectomy Device, X-track® Intracranial Distal Access Catheter, and NUMEN Silk® 3D Electronically Detachable Coil received NMPA approvals in ChinaSources

MicroPort MedBot Toumai® Laparoscopic Surgical Robot received NMPA approval in China and won several awardsSources

MicroPort® CRM Invicta™ Defibrillation leads received CE mark approval in EuropeSources

MicroPort Endovascular Talos® Thoracic Stent Graft System received NMPA approval in ChinaSources

MicroPort Urocare Single-use Flexible Digital Ureteroscope received the NMPA approval in ChinaSources

MicroPort Argus™ intravascular OCT system received NMPA approval in ChinaSources

MicroPort® inaugurated a training Center in BrazilSources

MicroPort® obtained 4 FDA approvals, including: MicroPort® Orthopedics EVOLUTION® Tibial ConesSources

58 products obtained NMPA's approval in China, including: MicroPort® Orthopedics Evolution® CCK Knee Revision SystemSources

And 6 products entered NMPA's "Green Path", including: MicroPort® Orthopedics Wrist Arthroplasty SystemSources

MicroPort® CardioFlow completed a strategic merger with MicroPort® CRM, building a comprehensive heart failure management solution spanning all etiologies, stages, and treatment pathways.Sources

MicroPort® obtained 7 FDA approvals, including: MicroPort® Orthopedics NEXUS® Femoral Stem.Sources

MicroPort® obtained 23 CE approvals, including: MicroPort® Endovastec™ Hector® Multi-Branch Thoracic Stent Graft System (custom certification).Sources

MicroPort® obtained 23 CE approvals, including: MicroPort EverPace™ IceMagic™ Cryoablation System.Sources

MicroPort® obtained 23 CE approvals, including: MicroPort® CRM MR-Conditional Mixed Pacing System and VEGA™ M lead.Sources

Over 30 products received NMPA Class III medical device registration, including: MicroPort® Coronary TomaHawk® Intravascular Lithotripsy Catheter and Firelimus® Drug-Eluting Balloon, MicroPort® CardioFlow AnchorMan® Left Atrial Appendage Closure System, MicroPort® CRM TEN Series 3.0T MRI-Conditional Pacemakers, MicroPort® Endovastec™ Cratos™ Thoracic Branch Stent Graft, MicroPort EverPace™ PulseMagic™ TrueForce® PFA Catheter, MicroPort® MedBot UniPath® Surgical Navigation System and Toumai® SP Single-Port Robot, MicroPort® VisionPower YINI® Cataract Phacoemulsification System, MicroPort® MicroVasive EZ-Eye™ 5100 GI Endoscopy System, MicroPort® Dentition YairDent® Dental Implant System.Sources

41 products were accepted into the NMPA’s 'Green Path', including: MicroPort® Endovastec™ Hector® Multi-Branch Thoracic Stent Graft, MicroPort® UniFlow Streamliner™ Implantable Tibial Nerve Stimulator, MicroPort EverPace™ EasyEcho™ Intracardiac Ultrasound Catheter, MicroPort NeuroScientific StraitPass™ Disposable Hematoma Aspiration Device.Sources

MicroPort® CRM VEGA™ M58 Pacing Lead approved in Australia, MicroPort® CardioFlow VitaFlow Liberty® Transcatheter Aortic Valve System approved in 15 countries, including Brazil and Morocco, MicroPort® MedBot Toumai® Remote Surgery System approved in 10 countries.Sources

TARGET-FIRST Trial results for MicroPort® Coronary Firehawk® Stent published in The New England Journal of Medicine and presented at ESC 2025, demonstrating safety of 1-month DAPT in low-risk AMI patients with complete revascularization.Sources

MicroPort® Coronary surpassed 10 million stent systems shipped and implanted globally.Sources

MicroPort® MedBot Toumai® Surgical Robot achieved over 100 global commercial installations.Sources

The Toumai® system also achieved multiple robotic surgery milestones, including: The world’s first commercial remote robotic surgery.Sources

The Toumai® system also achieved multiple robotic surgery milestones, including: The first FDA-IDE approved remote robotic surgery.Sources

The Toumai® system also achieved multiple robotic surgery milestones, including: The first remote robotic surgery in Europe.Sources

The Toumai® system also achieved multiple robotic surgery milestones, including: The first ultra-remote 5G robotic surgery at over 4,500 meters altitude.Sources

The Toumai® system also achieved multiple robotic surgery milestones, including: The first low-orbit satellite remote surgery.Sources

MicroPort® CardioFlow’s VitaFlow Liberty® Expands Global Presence with Key Milestones in Europe and Latin AmericaSources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑